SCHEMBL3526303

SCHEMBL3526303

Nc1nccc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c(F)c3)c12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT1 P17948 9/20 0.62
▸ LCK P06239 7/20 0.62
▸ FLT3 P36888 7/20 0.62
▸ CSF1R P07333 7/20 0.62
▸ FGFR1 P11362 6/20 0.62
▸ KIT P10721 6/20 0.62
▸ CSNK1D P48730 5/20 0.62
▸ ROCK1 Q13464 5/20 0.62
▸ NTRK2 Q16620 5/20 0.62
▸ LYN P07948 5/20 0.62
▸ BLK P51451 5/20 0.62
▸ PLK4 O00444 4/20 0.62
▸ AURKA O14965 4/20 0.62
▸ PIM1 P11309 4/20 0.62
▸ RPS6KB1 P23443 4/20 0.62
▸ RPS6KA3 P51812 4/20 0.62
▸ NEK2 P51955 4/20 0.62
▸ STK3 Q13188 4/20 0.62
▸ PLK3 Q9H4B4 4/20 0.62
▸ ROCK2 O75116 4/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3526761 0.91 FLT1 (0.75) FLT1LCKFLT3CSF1RFGFR1
SCHEMBL3528941 0.89 KDR (0.65) FLT1LCKFLT3CSF1RFGFR1
SCHEMBL4473254 0.85 KIT (0.83) FLT1LCKFLT3CSF1RFGFR1
SCHEMBL3526162 0.82 KDR (0.78) FLT1LCKFLT3CSF1RFGFR1
SCHEMBL4478648 0.80 FLT1 (0.79) FLT1LCKFLT3CSF1RFGFR1
SCHEMBL3532482 0.80 KDR (0.76) FLT1LCKFLT3CSF1RFGFR1
SCHEMBL3530481 0.79 KDR (0.78) FLT1LCKFLT3CSF1RFGFR1
SCHEMBL3526559 0.79 KDR (0.79) FLT1LCKFLT3CSF1RFGFR1
SCHEMBL3530171 0.78 KDR (0.78) FLT1LCKFLT3CSF1RFGFR1
SCHEMBL3528431 0.77 KDR (0.78) FLT1LCKFLT3CSF1RFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 — — US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 — — US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 — — US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 — — EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 — — US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 — — US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 — — US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 — — US disclosed
US-20050020619-A1 Thienopyridine kinase inhibitors ABBOTT LABORATORIES 2005-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020619-A1 Thienopyridine kinase inhibitors ABL1, MAP4K2, MAP4K5 FLT1 891/4885LCK 12/4885FLT3 45/4885
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK FLT1 613/4885LCK 3/4885FLT3 25/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK FLT1 613/4885LCK 3/4885FLT3 25/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK FLT1 613/4885LCK 3/4885FLT3 25/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK FLT1 613/4885LCK 3/4885FLT3 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback